[1] Rauner M, Wolfgang S, Pietschmann P. Osteoimmunology, 2007

[2] Riegel A et al. Human polymorphonuclear neutrophils express RANK and are activated by its ligand, RANKL.Eur J Immunol. 2012;42(4):975-81

[3] Nakashima T, Takayanagi H. Osteoclasts and the immune system, 2009

[4] Anandarajah AP, Schwarz EM. Bone loss in the spondyloarthropathies: role of osteoclast, RANKL, RANK and OPG in the spondyloarthropathies. Adv Exp Med Biol. 2009; 649: 85-99

[5] Bjarnason I, Takeuchi K. Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J Gastroenterol 2009; 44(19): 23-29

[6] Lee ChM, Genetos DC, Wong A, Yellowley CE. Prostaglandin expression profile in hypoxic osteoblastic cells. J Bone Miner Metab. 2009

[7] Vuolteennaho K, Moilanen T, Moilanen E. Non-Steroidal Anti-Inflammatory Drugs, Cyclooxygenase-2 and the Bone Healing Process. Basic & Clinical Pharmacology & Toxicology 2007; 102: 10–14

[8] Lee HW et al. Adiponectin Stimulates Osteoblast Differentiation Through Induction of COX2 in Mesenchymal Progenitor Cells. Stem Cells 2009; 27: 2254-2262

[9] Ramirez-Yanez G, Symons A. Prostaglandin E2 affects osteoblast biology in a dose-dependent manner: An in vitro study. Archives of Oral Biology 2012; 57(9): 1274-1281

[10] Harder AT, Yuehuei HA. The Mechanisms of the Inhibitory Effects of Nonsteroidal Anti-Inflammatory Drugs on Bone Healing. J ClinPharmacol. 2003; 43: 807-815

[11] BlackwellAK, Raisz LG, Pilbeam CC. Prostaglandins in bone: bad cop, good cop? Trends in Endocrinology and Metabolism 2009; 30(10): 1-8

[12] Thompson D &Paralkar V. M. Prostaglandin E2 receptors in bone formation. International Orthopaedics 2007; 31:767–772

[13] Blackwell KA, Raisz LG, Pilbeam CC. Prostaglandins in bone: bad cop, good cop? Trends in Endocrinology an Metabolism 2009; 30(10)

[14] Vega D, MaalofNM, Sakhaee K. The Role of RANK/RANKL/OPG: Clinical Implications. J ClinEndocrinMetab. 2007; 10: 3-10

[15] Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T Cells, Bone Loss and Mammalian Evolution. Annual Review of Immunology 2002; 20: 795-823

[16] Stolina M et al. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapies. Arthritis Research & Therapy 2009; 11(6)

[17] Boyce BF, Xing L. Biology of RANK, RANKL and osteoprotegerin. Arthritis Res. & Therapy 2007; 9(1): 1-7

[18] Kiechl S et al. The osteoprotegering/RANK/RANKL system: a bone key to vascular disease. Expert Rev CardiovascTher. 2006; 4(6): 801-811

[19] Lacey D L et al. Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab.Nature Reviews Drug Discovery2012; 11:401-419

[20] Zhao W er al. The Role of T Cells in Osteoporosis, an Update, Int J ClinExp Pathol.2009;2: 544-552

[21] RuddleNH, Akirav EM. Secondary lymphoid organs: responding to genetic and environmental cues in ontogeny and the immune response. J Immunol. 2009; 183(4): 2205-2212

[22] Leibrandt A, Penninger JM. RANK/RANKL: Regulators of Immune Responses and Bone Physiology. Ann.NY Acad. Sci. 2008; 1143: 123-150

[23] Rodriguez-Bores L, Barahona-Garrido J, Yamamoto-Furusho JK. Basic and clinical aspects of osteoporosis in inflammatory bowel disease, World J Gastroenterol. 2007; 13(46): 6156-6165

[24] Bernstein CN. Inflammatory bowel disease as secondary causes of osteoporosis. Curr. Osteoporos Rep. 2006; 4(3): 116-123

[25] Meier C, Plevy S. Therapy insight: how the gut talks to the joints—inflammatory bowel disease and the spondyloarthropaties. Nat ClinPractRheumatol. 2007; 3(11): 667-674

[26] Fries W, Gastrointestinal lesions associated with spondyloarthropathies. World J Gastroenterol. 2009; 15(20): 2443-2448

[27] Williams JE. Mucosal Immunity – Portal to the Interior: Viral Pathogenesis and Natural Compounds that Restore Mucosal Immunity and Modulate Inflammation. Alternative Medicine Review 2003; 8(4): 395-405

[28] Winkler P, Ghadimi D, Schrezenmeir J, Kraehenbuhl JP. Molecular and Cellular Basis of Microflora-Host Interactions. The Journal of Nutrition 2007; 137: 756-768

[29] Rodriguez-Bores L et al. Basic and clinical aspects of osteoporosis in inflammatory bowel disease. 2007

[30] Lanas A, Sopeña F, Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications. GastroenterolClin North Am. 2009; 38(2): 333-52

[31] Maiden L. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel. ClinGastroenterolHepatol. 2007; 5(9): 1040-1045

[32] O’Connor JP, Lysz T. Celecoxib, NSAIDs and the skeleton, Drugs Today 2008; 44(9): 693-709

[33] Harder AT, An YH. The mechanisms of the Inhibitory Effects of Nonsteroidal Anti-Inflammatory Drugs on Bone Healing. Journal of Clinical Pharmacology 2003; 43: 807-815

[34] Boursinos LA et al. Do steroids, conventional non-steroidal anti-inflammatory drugs and selective Cox-2 inhibitors adversely affect fracture healing? J Musculoskelet Neuronal Interact 2009; 9(1): 44-52

[35] Vuolteennaho K, Moilanen T, Moilanen E. 2007

[36] Meier C, Plevy S. Therapy insight: how the gut talks to the joints, 2007

[37] Chang JK, Li CJ, Liao HJ, Wang CK, Wang GJ, Ho ML. Anti-inflammatory drugs suppress proliferation and induce apoptosis through altering expressions of cell cycle regulators and pro-apoptotic factors in cultured human osteoblasts. Toxicology 2009; 258(2-3): 148-156

[38] Hernandez RK et al. Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database. Acta Orthopaedica 2012; 83(6): 653–660

[39] Hanai H, Sugimoto K. Curcumin has bright prospects for the treatment of inflammatory bowel disease. CurrPharm Des. 2009;15(18): 2087-94.